Forecasting outcomes in anti-NMDAR encephalitis: Clearer prognostic markers needed.

• Rüegg S From the Department of Neurology (S.R.), University Hospital Basel, Switzerland; Hospital for Sick Children (E.A.Y.), Division of Neurology, SickKids Research Institute, Neurosciences and Mental Health, University of Toronto, Canada; and French Reference Center on Paraneoplastic Neurological Syndrome (J.H.), Hospices Civils de Lyon, Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310, Université de Lyon-Université Claude Bernard Lyon 1, France. Stephan.Rueegg@usb.ch.
• Yeh EA From the Department of Neurology (S.R.), University Hospital Basel, Switzerland; Hospital for Sick Children (E.A.Y.), Division of Neurology, SickKids Research Institute, Neurosciences and Mental Health, University of Toronto, Canada; and French Reference Center on Paraneoplastic Neurological Syndrome (J.H.), Hospices Civils de Lyon, Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310, Université de Lyon-Université Claude Bernard Lyon 1, France.
• Honnorat J From the Department of Neurology (S.R.), University Hospital Basel, Switzerland; Hospital for Sick Children (E.A.Y.), Division of Neurology, SickKids Research Institute, Neurosciences and Mental Health, University of Toronto, Canada; and French Reference Center on Paraneoplastic Neurological Syndrome (J.H.), Hospices Civils de Lyon, Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310, Université de Lyon-Université Claude Bernard Lyon 1, France.

Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Humans

Prognosis

Receptors, N-Methyl-D-Aspartate